News Articles
Latest articles, insights, and updates from the blog.
Contact Ketamine Troche
Send corrections, provider questions, or advertising inquiries.
Non-Drug Approaches Boost Ketamine Troche Outcomes
New research explores how behavioral therapy and neuroplasticity techniques can enhance ketamine troche treatment outcomes for depression.
Expert Insights: Key Ketamine Patient Considerations
Dr. Benjamin Brody highlights critical patient considerations for ketamine treatment at ASCP 2026, with key implications for troche therapy protocols.
Boston Clinics Spotlight Ketamine's Mental Health Role
Boston-area clinics are spotlighting ketamine for depression and anxiety. Here's what their approach means for patients using at-home ketamine troches.
TMS vs. Ketamine: What TRD Patients Should Know
Medical Daily covers when to try ketamine or TMS for treatment-resistant depression. Here's what it means for patients weighing ketamine troches.
IV Ketamine in the News: What Troche Users Should Know
A FOX 4 Kansas City segment spotlights IV ketamine therapy. Here's what the growing media attention means for ketamine troche patients and at-home access.
Ketamine & Workers' Comp: What Alabama's Rules Mean
Alabama workers' comp cases are testing ketamine therapy coverage standards. Here's what this legal shift means for troche access and reimbursement in 2026.
Esketamine Clinic Protocols: What Troche Patients Should Know
New esketamine clinic-protocol guidance shows why sublingual ketamine troches stay a flexible, accessible alternative for many treatment-resistant patients.
NMDA Side Effects: What the Data Means for Troche Users
New research on NMDA antagonist side effects and discontinuation rates offers practical guidance for ketamine troche patients managing treatment-resistant depression.
Ketamine Dropout Rates: The Case for Troche Optimization
New clinical data on NMDA antagonist side effects and dropout rates reveals why troche dosing flexibility may improve long-term treatment adherence.
Trump EO Could Reshape Ketamine Troche Access in 2026
President Trump's 2026 executive order on psychedelic research signals a regulatory shift that could affect compounded ketamine troche access and prescribing.
Ketamine Dropout Rates: Why Delivery Format Changes Everything
New clinical data on NMDA antagonist side effects and dropout rates shows why ketamine troche delivery may offer a meaningful tolerability advantage.
Side Effects & Stopping Rates: What NMDA Data Means
New data on NMDA antagonist side effects and discontinuation rates has direct implications for ketamine troche patients managing treatment-resistant depression.